Patents by Inventor Patrick PAUWELS

Patrick PAUWELS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunotherapy markers
    Patent number: 12710426
    Abstract: The present invention relates to the identification and use of markers indicative for the response of a subject to immunotherapy as anti-cancer treatment. The markers are particularly useful in predicting response of a subject to immunotherapy with PD-1 or PD-L1 antagonists in the treatment of cancer. PD-1 and PD-L1 antagonists are typically used as immunotherapy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: August 18, 2026
    Assignees: VITO NV, Universiteit Antwerpen
    Inventors: Eline Berghmans, Geert Baggerman, Evelien Smits, Patrick Pauwels
  • Cell-Based Therapeutics Targeting CD70
    Publication number: 20240115606
    Abstract: The invention provides a natural killer (NK) cell engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises the extracellular domain of CD27 or a CD70-binding portion thereof, as well as compositions comprising the engineered NK cell, methods for producing the engineered NK cell, and therapeutic applications of the engineered NK cell, such as for treating neoplastic diseases.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 11, 2024
    Inventors: Astrid VAN DEN EYNDE, Evelien SMITS, Patrick PAUWELS, Julie JACOBS
  • IMMUNOTHERAPY MARKERS
    Publication number: 20230051633
    Abstract: The present invention relates to the identification and use of markers indicative for the response of a subject to immunotherapy as anti-cancer treatment. The markers are particularly useful in predicting response of a subject to immunotherapy with PD-1 or PD-L1 antagonists in the treatment of cancer. PD-1 and PD-L1 antagonists are typically used as immunotherapy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma.
    Type: Application
    Filed: September 14, 2020
    Publication date: February 16, 2023
    Inventors: Eline BERGHMANS, Geert BAGGERMAN, Evelien SMITS, Patrick PAUWELS